Canaccord analyst Richard Close said a court filing in the case of the FTC versus Steven Dorfman gives him increased confidence that Health Insurance Innovations is not a target of the FTC and has "minimal, if any," legal concerns over this matter. His read of the documents leads Close to believe the FTC's position is that Health Insurance Innovations is not responsible for demonstrating that products sold by Simple Health provide benefits and value and the FTC "appears not to be shifting any blame" to the company, the analyst tells investors. He keeps a Buy rating and $62 price target on Health Insurance Innovations shares.